Pfizer Covid vaccine cuts Omicron hospitalisations by 70% in real-world study | Mint
Active Stocks
Mon Feb 26 2024 09:48:10
  1. Tata Steel share price
  2. 144.80 -0.48%
  1. ITC share price
  2. 412.65 0.26%
  1. Power Grid Corporation Of India share price
  2. 287.50 1.88%
  1. State Bank Of India share price
  2. 763.55 0.55%
  1. HDFC Bank share price
  2. 1,426.10 0.37%
Business News/ News / World/  Pfizer Covid vaccine cuts Omicron hospitalisations by 70% in real-world study
BackBack

Pfizer Covid vaccine cuts Omicron hospitalisations by 70% in real-world study

The study was based on more than 211,000 positive Covid test results from 15 November to 7 December , around 78,000 of which were attributed to Omicron.

The 78,000 results are not confirmed Omicron cases, meaning the study is not able to draw conclusive findings about the variant labelled ‘of concern’ by the World Health Organization. (AFP)Premium
The 78,000 results are not confirmed Omicron cases, meaning the study is not able to draw conclusive findings about the variant labelled ‘of concern’ by the World Health Organization. (AFP)

Two doses of Pfizer-BioNTech's Covid-19 vaccine appear to have given 70% protection against hospitalisation in South Africa in recent weeks, a major real-world study on the potential impact of Omicron showed on Tuesday, as the country battles a spike in infections linked to the new variant.

The study released by South Africa's largest private health insurance administrator, Discovery Health, was based on more than 211,000 positive Covid-19 test results from 15 November  to 7 December , around 78,000 of which were attributed to Omicron.

The 78,000 results are not confirmed Omicron cases, meaning the study is not able to draw conclusive findings about the variant labelled "of concern" by the World Health Organization.

South African scientists have so far confirmed around 550 Omicron sequences, with the variant accounting for 78% of sequences from November, more than the previously dominant Delta variant.

South Africa alerted the world to Omicron late last month, triggering alarm that it could cause another surge in global infections, and leading to the imposition of travel restrictions on southern Africa. South Africa's daily infections have since risen to around 20,000 in recent days.

Based on analysis by Discovery's clinical research and actuarial teams, and in collaboration with South Africa's Medical Research Council (SAMRC), the real-world study calculated that two doses of Pfizer-BioNTech offered 70% protection against hospitalisation during the recent surge in cases and 33% protection against infection.

South Africa is using the Pfizer-BioNTech and Johnson & Johnson vaccines in its Covid-19 immunisation campaign, with more than 20 million Pfizer doses administered so far.

It concluded that there was a higher risk of reinfection during the fourth wave than during previous waves and that the risk of hospitalisation among adults diagnosed with Covid-19 was 29% lower than during the country's first wave early last year.

Children appeared to have a 20% higher risk of hospital admission with complications during the fourth wave than during the first, despite a very low absolute incidence, it said.

Discovery cautioned that the study's findings should be considered preliminary.

Glenda Gray, SAMRC president, said it was important that the Pfizer-BioNTech vaccine appeared to be offering good protection against severe disease and hospitalisation.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Check all the latest action on Budget 2024 here. Download The Mint News App to get Daily Market Updates.
More Less
Published: 14 Dec 2021, 02:52 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App